Aardvark Therapeutics, Inc.
AARD
$13.88
$0.322.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 46.73% | -0.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.70% | 51.37% | |||
| Operating Income | -11.70% | -51.37% | |||
| Income Before Tax | -13.57% | -54.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.57% | -54.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.57% | -54.32% | |||
| EBIT | -11.70% | -51.37% | |||
| EBITDA | -11.72% | -51.33% | |||
| EPS Basic | -13.44% | 6.12% | |||
| Normalized Basic EPS | -13.75% | 6.02% | |||
| EPS Diluted | -13.44% | 6.12% | |||
| Normalized Diluted EPS | -13.75% | 6.02% | |||
| Average Basic Shares Outstanding | 0.11% | 64.39% | |||
| Average Diluted Shares Outstanding | 0.11% | 64.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||